Citadel Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Citadel Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.44M	Buy	+468,712	New	+$7.22M	﹤0.01%	3936
2025 Q3	–	Sell	-7,077	Closed	-$255K	–	14124
2025 Q2	$255K	Buy	+7,077	New	+$185K	﹤0.01%	10170
2022 Q4	–	Sell	-1	Closed	-$14K	–	15460
2022 Q3	$14K	Sell	1 -2	-67%	-$49.1K	﹤0.01%	12183
2022 Q2	$93K	Buy	+3	New	+$221K	﹤0.01%	11487
2022 Q1	–	Hold	0	–	–	–	12747
2021 Q4	–	Sell	-1	Closed	-$318K	–	12965
2021 Q3	$374K	Buy	+1	New	+$487K	﹤0.01%	10566
2021 Q2	–	Sell	-1	Closed	-$776K	–	14444
2021 Q1	$776K	Buy	+1	New	+$765K	﹤0.01%	8714
2020 Q4	–	Hold	0	–	-$67K	–	11526
2020 Q3	–	Sell	-1	Closed	-$606K	–	9484
2020 Q2	$270K	Buy	+1	New	+$438K	﹤0.01%	8074
2020 Q1	–	Hold	0	–	–	–	8944
2018 Q4	–	Hold	0	–	-$22K	–	9762
2018 Q3	–	Hold	0	–	–	–	8997
2017 Q2	–	Hold	0	–	-$119K	–	8067
2017 Q1	–	Hold	0	–	–	–	6794
2016 Q4	–	Hold	0	–	-$151K	–	7840
2016 Q3	–	Hold	0	–	–	–	6464
2016 Q2	–	Hold	0	–	–	–	4890
2016 Q1	–	Hold	0	–	–	–	4533
2015 Q4	–	Hold	0	–	–	–	2919
2015 Q3	–	Hold	0	–	–	–	3704
2015 Q2	–	Hold	0	–	–	–	7762
2015 Q1	–	Hold	0	–	–	–	7596
2014 Q4	–	Hold	0	–	–	–	8183
2014 Q2	–	Hold	0	–	-$240K	–	8306
2014 Q1	–	Hold	0	–	–	–	5304

Other funds holding TNXP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JHC

Jones Hill Capital New York $466M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's TNXP Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tonix Pharmaceuticals (TNXP) in Q1 2026: 468,712 shares worth $6.44M. The stake represents ﹤0.01% of the portfolio and ranks #3936 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TNXP as recently as Q2 2025.

Citadel Advisors first reported a position in TNXP in Q2 2020 and has held it in 7 quarters since. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

Citadel Advisors held 468,712 shares of Tonix Pharmaceuticals worth $6.44M as of Q1 2026.
Tonix Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
Tonix Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3936 holding.
Citadel Advisors first reported a position in Tonix Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.